New coronavirus infection and pregnancy

2021 ◽  
Vol 69 (6) ◽  
pp. 71-80
Author(s):  
Kristina A. Oganyan ◽  
Kira V. Shalepo ◽  
Alevtina M. Savicheva ◽  
Olesya N. Bespalova ◽  
Igor Yu. Kogan
Keyword(s):  
Pregnant Women ◽  
Perinatal Outcomes ◽  
Multiple Organ ◽  
Laboratory Research ◽  
Low Grade ◽  
Upper Respiratory Tract ◽  
Gastrointestinal Complications ◽  
Runny Nose ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The novel coronavirus infection (COVID-19), first reported in Wuhan, China in December 2019, is dangerous for pregnant women, and the probability of infection is the same as in the general population. COVID-19 may be transmitted from person to person through two different routes: airborne and direct contact. Diagnosis of COVID-19 requires the detection of SARS-CoV-2 RNA by reverse transcription polymerase chain reaction. The main biomaterial for laboratory research is discharge from the nasopharynx and (or) oropharynx. The incubation period for COVID-19 is thought to last from 2 to 14 days, with a median time of 45 days. The causative agent of COVID-19 can be detected in the upper respiratory tract 12 days before and within 714 days after the onset of symptoms. The disease can occur with mild-to-moderate severity, and manifests itself as a respiratory infection (runny nose, sore throat, low-grade fever, with no viral pneumonia and hypoxia). Severe COVID-19 may develop pneumonia, respiratory distress syndrome, sepsis, septic shock, cardiomyopathy, arrhythmia, renal failure, and other complications up to multiple organ failure. Pregnant women with COVID-19 may have complications of pregnancy, such as miscarriage, premature discharge of amniotic fluid, and premature birth. There are no reports of vertical transmission, but some newborns develop intrauterine growth retardation and life-threatening gastrointestinal complications. Thus, pregnant women with a confirmed diagnosis or suspicion of COVID-19 are at high risk for developing pregnancy complications and adverse perinatal outcomes. Currently, information is being collected on COVID-19 cases in pregnant women, the course of infection, and perinatal outcomes.

scholarly journals COVID-19 vaccination of pregnant women: state-of-the-art

2021 ◽  
Vol 5 (11) ◽  
pp. 768-772
Author(s):  
A.A. Girina ◽  
◽  
A.L. Zaplatnikov ◽  
V.I. Svintsitskaya ◽  
S.D. Izhogina ◽  
...  
Keyword(s):  
Pregnant Women ◽  
State Of The Art ◽  
Severe Disease ◽  
Perinatal Outcomes ◽  
Professional Associations ◽  
Disease Course ◽  
Complete Control ◽  
Outcome Monitoring ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Despite efforts made by the world community to battle the novel coronavirus infection, we are still unable to take complete control of virus spread. One of the causes of this issue is inadequate coverage of vaccination. Meanwhile, disease course in specific populations is associated with the risks of severe complications and lethal outcome. Infection of pregnant women is of particular concern. This paper addresses recent data on vaccination against the COVID-19 infection in pregnant women, including those with risk of severe disease course and unfavorable outcome. Monitoring the health of women infected with SARS-CoV-2 during gestation demonstrates unfavorable effects of the COVID-19 infection on the course and outcome of pregnancy. On the other hand, observational programs have demonstrated that vaccination has no effects on pregnancy course and perinatal outcomes. A view of the WHO and professional associations on the vaccination of pregnant women, particularly those from risk groups of severe COVID-19 course, is discussed. The importance of a personalized and balanced approach to COVID-19 vaccination of pregnant women involving the assessment of risks and benefits for the mother and child is emphasized. KEYWORDS: novel coronavirus infection, COVID-19, vaccination, immunization, pregnant women, risk group. FOR CITATION: Girina A.A., Zaplatnikov A.L., Svintsitskaya V.I., Izhogina S.D. COVID-19 vaccination of pregnant women: state-of-the-art. Russian Medical Inquiry. 2021;5(11):768–772 (in Russ.). DOI: 10.32364/2587-6821-2021-5-11-768-772.

Impact of Novel Coronavirus (COVID-19) on Pregnant Women: A Review

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Saima Habeeb ◽  
Manju Chugani
Keyword(s):  
Pregnant Women ◽  
Vertical Transmission ◽  
Respiratory Infections ◽  
Age Groups ◽  
Well Being ◽  
Fetal Outcome ◽  
Global Public Health ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
The Impact

: The novel coronavirus infection (COVID‐19) is a global public health emergency.Since its outbreak in Wuhan, China in December 2019, the infection has spread at an alarming rate across the globe and humans have been locked down to their countries, cities and homes. As of now, the virus has affected over 20million people globally and has inflicted over 7 lac deaths. Nevertheless, the recovery rate is improving with each passing day and over 14 million people have recuperated so far. The statistics indicate that nobody is immune to the disease as the virus continues to spread among all age groups; newborns to the elders, and all compartmentsincluding pregnant women. However, pregnant women may be more susceptible to this infection as they are, in general, highly vulnerable to respiratory infections. There is no evidence for vertical transmission of the COVID-19 virus among pregnant women, but an increased prevalence of preterm deliveries. Besides this, the COVID-19 may alter immune response at the maternal-fetal interface and affect the well-being of mothers as well as infants. Unfortunately, there is limited evidence available in the open literature regarding coronavirus infection during pregnancy and it now appears that certain pregnant women have infected during the present 2019-nCoV pandemic. In this short communication, we study the impact of the COVID-19 infection on vertical transmission and fetal outcome among pregnant women.

scholarly journals Smell disorders associated with COVID-19 infection

2021 ◽  
Vol 37 (1) ◽  
Author(s):  
Mohammad Waheed El-Anwar ◽  
Sherif Mamdoh Mohamed ◽  
Ahmed Hassan Sweed
Keyword(s):  
Web Of Science ◽  
Cochrane Library ◽  
Upper Respiratory Tract ◽  
Nasal Blockage ◽  
Runny Nose ◽  
Red Flag ◽  
Upper Respiratory ◽  
Novel Coronavirus ◽  
Smell Disorders ◽  
Smell Identification

Abstract Background We performed a search in the PubMed databases, Web of Science, LILACS, MEDLINE, SciELO, and Cochrane Library using the keywords COVID-19, Novel coronavirus, corona, 2019-nCoV, SARS-CoV-2, ENT, nose, anosmia, hyposmia, smell, olfactory, ORL, different ENT related symptoms. We reviewed published and peer-reviewed studies that reported the ENT manifestations in COVID-19 laboratory-confirmed positive patients. Main text Within the included 2549 COVID-19 laboratory-confirmed positive patients, smell affection was reported in 1453 patients (57%). The other reported ENT manifestations were taste disorder (49.2%), headache (42.8%), nasal blockage (26.3%), sore throat (25.7%), runny nose or rhinorrhea (21.3%), upper respiratory tract infection (URTI) (7.9%), and frequent sneezing (3.6%). Conclusion Smell affection in COVID-19 is common and could be one of the red flag signs in COVID-19 infection. With a sensitivity of utilized questionnaire in smell identification, a homogenous universal well-defined COVID-19 questionnaire is needed to make the COVID-19 data collection more sensible.

Risk factors and features of COVID-19 course in pregnant women: a comparative analysis of epidemic outbreaks in 2020 and 2021

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. 421-427
Author(s):  
Tatiana E. Belokrinitskaya ◽  
Nataly I. Frolova ◽  
Kristina A. Kolmakova ◽  
Evgeniya A. Shametova
Keyword(s):  
Risk Factors ◽  
Computed Tomography ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Ethnic Group ◽  
Sore Throat ◽  
Iron Deficiency Anemia ◽  
Deficiency Anemia ◽  
Runny Nose ◽  
Coronavirus Infection

Aim. To compare risk factors, features of COVID-19 course and outcomes in pregnant women during epidemic increase in incidence in 2020 and 2021. Materials and methods. The study included 163 pregnant women with laboratory-confirmed SARS-CoV-2 infection within May December 2020 (1st2nd waves of the epidemic) and 158 pregnant women who had new coronavirus infection within May August 2021 (3rd wave of the epidemic). Patients in all groups were comparable in age (1835 years), social status, parity, body mass index, and had no known risk factors for COVID-19. Results. Iron deficiency anemia, smoking, belonging to the Buryat ethnic group were recognized as persistent risk factors for COVID-19 in pregnant women. Over the 1st year of the pandemic, in pregnant women, the following clinical manifestations of novel coronavirus infection were commonly seen: anosmia (87.7%), somnolence (68.7%), shortness of breath even with a mild lung damage (68.1%). In the 3rd wave of the 2nd year of the pandemic, the leading signs and symptoms were cough (70.3% vs 38.7%, p0.001), runny nose (46.2% vs 3.7%, p0001), sore throat (367% vs 37%, p0.001); an increase in body temperature above 38C (19.6% vs 7,4%, p=0.006), pneumonia detected by computed tomography (61.4% vs 21.4%; p0.001). There was a significant increase in the incidence of severe lung lesions (with computed tomography 34: 17.7% vs 4.9%; p0.001) and admissions to intensive care units (11.4% vs 6.4%; p= 0041). There was a need for invasive mechanical ventilation (1.89% vs 0%; p=0.118). There was 1 death (0.63% vs 0%; p= 0.492), which was associated with the fulminant course of COVID-19. Conclusion. Persistent COVID-19 confounders in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, smoking, and belonging to the Buryat ethnic group. The clinical course of SARS-CoV-2 infection has changed and became more unfavorable: symptoms of acute respiratory disease (cough, runny nose, sore throat) began to prevail, the rate and severity of pneumonia and rate of mortality increased.

NEW CORONOVIRUS INFECTION: CLINICAL AND PATHOGENETIC ASPECTS OF COVID-19 IN PREGNANT WOMEN

2021 ◽  
pp. 57-62
Author(s):  
Allakhyarov D.Z. ◽  
Petrov Yu.A. ◽  
Chernavsky V.V.
Keyword(s):  
Pregnant Women ◽  
The Body ◽  
World Health ◽  
Upper Respiratory Tract ◽  
Global Pandemic ◽  
High Prevalence ◽  
Coronavirus Infection ◽  
The Moment ◽  
Health Organization ◽  
The Impact

This article presents reviews of literature sources on the clinical and pathogenetic aspects of the course of a new coronovirus infection in pregnant women, in order to analyze the features of the course of COVID-19 in pregnant women and to assess the impact of infection on the body of a woman and a fetus. Pregnancy is a special physiological condition, during which a number of changes occur in the body, not only in the hormonal status, but also in the immune system. The urgency of this problem is due to the high prevalence of new coronavirus infection among the population. On March 12, 2020, the World Health Organization (WHO), as a result of the dynamic development of the epidemic in many countries and continents, declared a global pandemic of the contagious disease COVID-19 caused by the SARS-CoV-2 virus. According to available studies, pregnant women are more susceptible to a more severe course of infectious diseases affecting the upper respiratory tract. According to various studies, a new coronavirus infection can lead to premature birth, miscarriage, and preeclampsia. Separate studies show increased mortality in pregnant women diagnosed with COVID-19. The SARS-CoV-2 virus does not have a direct teratogenic effect on the fetus, but it can indirectly lead to harmful effects on the developing organism. Special attention should be paid to the issue of vaccination of pregnant women against a new coronavirus infection, at the moment there is no accurate data on the effect of the vaccine on the body of the pregnant woman and the fetus. In this regard, the question of the impact of a new coronavirus infection on the course of pregnancy has become relevant.

scholarly journals COVID-19. A review

2020 ◽  
Vol 90 (2) ◽  
Author(s):  
Irappa Madabhavi ◽  
Malay Sarkar ◽  
Nagaveni Kadakol
Keyword(s):  
Distress Syndrome ◽  
Case Fatality ◽  
Genomic Analysis ◽  
Multiple Organ ◽  
Low Grade ◽  
Epidemic Outbreak ◽  
Wuhan City ◽  
Novel Coronavirus ◽  
The Universe ◽  
Highly Virulent

The enduring epidemic outbreak which started in Wuhan city of China, in December 2019 caused by the 2019 novel coronavirus (COVID- 19) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created a dangerous and deadly Public Health disaster of International apprehension, with cases confirmed in several countries. This novel community health trouble is frightening the universe with clinical, psychological, emotional, collapse of health system and economical slowdown in each and every part of the world infecting nearly 200 countries. A highly virulent and pathogenic COVID-19 viral infection with incubation period ranging from two to fourteen days, transmitted by breathing of infected droplets or contact with infected droplets, belongs to the genus Coronavirus with its high mutation rate in the Coronaviridae. The likely probable primary reservoir could be bats, because genomic analysis discovered that SARSCoV-2 is phylogenetically interrelated to SARS-like bat viruses. The transitional resource of origin and transfer to humans is not known, however, the rapidly developing pandemic has confirmed human to human transfer. Approximately 1,016,128 reported cases, 211,615 recovered cases and 53,069 deaths of COVID-2019 have been reported to date (April 2, 2020). The symptoms vary from asymptomatic, low grade pyrexia, dry cough, sore throat, breathlessness, tiredness, body aches, fatigue, myalgia, nausea, vomiting, diarrhea, to severe consolidation and pneumonia, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction leading to death with case fatality rate ranging from 2 to 3%.

scholarly journals Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients

Acta Naturae ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 79-84
Author(s):  
Airat F. Khalirakhmanov ◽  
Kamilla F. Idrisova ◽  
Raushaniya F. Gajfullina ◽  
Sergey V. Zinchenko ◽  
Rustem I. Litvinov ◽  
...  
Keyword(s):  
Multiple Organ ◽  
Pulmonary Insufficiency ◽  
The Novel ◽  
Thromboembolic Complications ◽  
Short Period ◽  
Prevention And Treatment ◽  
Organ Failures ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Hemostatic Disorders

The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December 2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this article was being written, the number of infected and deceased patients continued to grow worldwide. Most patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decompensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases, local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. Despite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have been identified and measures for specific prevention and correction of thrombosis have been developed. This review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible approaches to their early diagnosis, prevention, and treatment.

scholarly journals Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020

2020 ◽  
Vol 19 (4) ◽  
pp. 2630 ◽  
Author(s):  
V. B. Grinevich ◽  
I. V. Gubonina ◽  
V. L. Doshchitsin ◽  
Yu. V. Kotovskaya ◽  
Yu. A. Kravchuk ◽  
...  
Keyword(s):  
Gastrointestinal Disease ◽  
Multiple Organ ◽  
Adverse Outcomes ◽  
Chronic Obstructive ◽  
The Novel ◽  
Vulnerable Group ◽  
Obstructive Pulmonary Disease ◽  
Medical Facilities ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The pandemic of the novel coronavirus infection (COVID-19), caused by SARS‑CoV‑2, has become a challenge to healthcare systems in all countries of the world. Patients with comorbidity are the most vulnerable group with the high risk of adverse outcomes. The problem of managing these patients in context of a pandemic requires a comprehensive approach aimed both at the optimal management in self-isolated patients not visiting medical facilities, and management of comorbidities in patients with COVID-19. The presented consensus covers these two aspects of managing patients with cardiovascular disease, diabetes, chronic obstructive pulmonary disease, gastrointestinal disease, and also pay attention to the multiple organ complications of COVID-19.

scholarly journals Positive Anti-SSA/Ro Antibody in a Woman with SARS-CoV-2 Infection Using Immunophenotyping: A Case Report

Medicina ◽  
2020 ◽  
Vol 56 (10) ◽  
pp. 521
Author(s):  
Po-I Huang ◽  
Ting-Chun Lin ◽  
Feng-Cheng Liu ◽  
Yi-Jung Ho ◽  
Jeng-Wei Lu ◽  
...  
Keyword(s):  
Antiphospholipid Antibodies ◽  
Clinical Case ◽  
Asymptomatic Infection ◽  
Upper Respiratory Tract ◽  
Severe Infections ◽  
Respiratory Tract Illness ◽  
Coronavirus Infection ◽  
Upper Respiratory ◽  
Novel Coronavirus ◽  
Autoantibody Level

The clinical spectrum of novel coronavirus infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia, with respiratory failure and even death. Autoantibodies, especially antiphospholipid antibodies, can occur in severe infections. Other autoantibodies are seldom reported. Here, a 60-year-old female patient without dry-mouth symptoms detected positive for anti-60 kDa SSA/Ro antibodies on day 43 after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To investigate this unique clinical case of SARS-CoV-2 infection, immunological characteristics of this case were detected by using flow cytometry and were compared to the other three groups of patients—health subjects, 2019 novel coronavirus disease (COVID-19) recovery patients, and Sjögren’s syndrome (SS) patients. Monitoring the autoantibody level and the development of subsequently related autoimmune diseases are warranted after SARS-CoV-2 infection.

Sign in / Sign up

Export Citation Format

Share Document